Malaria elimination will be possible only with serious attempts to address 
asymptomatic infection and chronic infection by both Plasmodium falciparum and 
Plasmodium vivax. Currently available drugs that can completely clear a human of 
P. vivax (known as "radical cure"), and that can reduce transmission of malaria 
parasites, are those in the 8-aminoquinoline drug family, such as primaquine. 
Unfortunately, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency 
risk having severe adverse reactions if exposed to these drugs at certain doses. 
G6PD deficiency is the most common human enzyme defect, affecting approximately 
400 million people worldwide.Scaling up radical cure regimens will require 
testing for G6PD deficiency, at two levels: 1) the individual level to ensure 
safe case management, and 2) the population level to understand the risk in the 
local population to guide Plasmodium vivax treatment policy. Several technical 
and operational knowledge gaps must be addressed to expand access to G6PD 
deficiency testing and to ensure that a patient's G6PD status is known before 
deciding to administer an 8-aminoquinoline-based drug.In this report from a 
stakeholder meeting held in Thailand on October 4 and 5, 2012, G6PD testing in 
support of radical cure is discussed in detail. The focus is on challenges to 
the development and evaluation of G6PD diagnostic tests, and on challenges 
related to the operational aspects of implementing G6PD testing in support of 
radical cure. The report also describes recommendations for evaluation of 
diagnostic tests for G6PD deficiency in support of radical cure.